Noubar Afeyan

Noubar Afeyan is the founder and CEO of Flagship Pioneering, a Cambridge venture capital firm that has created more than 100 scientific ventures including Moderna, Seres Therapeutics, and Rubius Therapeutics. Afeyan, an Armenian-American entrepreneur with a PhD in biochemical engineering from MIT, recognized the commercial potential of Rossi's mRNA reprogramming discovery and provided the initial seed funding and incubation infrastructure that enabled Moderna's creation. Flagship's venture lab model involves providing capital, scientific expertise, and management support to early-stage companies, with Flagship typically retaining significant equity and board control. Afeyan's decision to fund Moderna was based on his thesis that mRNA could become a platform technology applicable across multiple therapeutic areas, not merely a single-product opportunity.

Noubar Afeyan has served as Moderna's chairman since its founding and has been the architect of the company's strategic vision and capital structure. Under his leadership, Flagship Pioneering has built a portfolio of platform biotechnology companies that leverage scientific breakthroughs to create new therapeutic modalities. Afeyan has been instrumental in Moderna's financing strategy, including the 2018 IPO that raised $604 million and valued the company at $7.5 billion, and the subsequent capital raises that funded pandemic-scale manufacturing expansion. His vision of Moderna as a platform company rather than a product company has shaped the company's strategy of maintaining a broad pipeline across multiple therapeutic areas. Afeyan's continued involvement provides strategic continuity and access to Flagship's network of scientific and financial resources.

Noubar Afeyan was born in 1962 in Beirut. Education: McGill University; Massachusetts Institute of Technology.